tiprankstipranks
Trending News
More News >
Chia Tai Enterprises International Limited (HK:3839)
:3839
Advertisement

Chia Tai Enterprises International (3839) AI Stock Analysis

Compare
0 Followers

Top Page

HK:3839

Chia Tai Enterprises International

(OTC:3839)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 4o)
Rating:71Outperform
Price Target:
HK$10.00
▲(11.11% Upside)
Chia Tai Enterprises International's stock is supported by strong technical momentum and reasonable valuation. However, the lack of positive cash flow is a significant risk that could impact future performance. The stock's overbought condition suggests caution in the short term.

Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)

Chia Tai Enterprises International Business Overview & Revenue Model

Company DescriptionChia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, Biochemical and Industrial. The Biochemical segment manufactures and sells CTC premix and CTC hydrochloride products, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance feed efficiency under the Shihao and Citifac brands. The Industrial segment engages in the sale, leasing, and servicing of caterpillar machinery equipment, including excavators, power generators, bulldozers, and compactors, as well as spare parts; and manufacture and sale of carburetors and automotive parts for automobile and motorcycle manufacturers. The company was incorporated in 1987 and is based in Central, Hong Kong. Chia Tai Enterprises International Limited is a subsidiary of Charoen Pokphand Foods Public Company Limited.
How the Company Makes MoneyChia Tai Enterprises International generates revenue through a diversified business model that includes the sale of agricultural products such as animal feed, seeds, and fertilizers. The company leverages its extensive distribution network to reach farmers and agricultural businesses, ensuring a steady demand for its products. Additionally, the company's involvement in the consumer goods sector allows it to tap into the retail market, offering a range of products that cater to household needs. Strategic partnerships with local and international businesses also play a crucial role in expanding its market reach and enhancing its revenue streams. The company's earnings are further supported by its commitment to innovation and product development, which helps maintain its competitive edge in the industry.

Chia Tai Enterprises International Financial Statement Overview

Summary
Chia Tai Enterprises International shows strong revenue growth and improving profit margins, suggesting positive operational momentum. The balance sheet indicates financial stability with low leverage, but the absence of positive cash flow presents a significant risk that requires better cash management.
Income Statement
70
Positive
Chia Tai Enterprises International has shown a strong revenue growth rate with a significant increase from 2023 to 2024. The gross profit margin stands at 15.90% for 2024, depicting healthy profitability. Additionally, the net profit margin improved to 3.63%, indicating better cost management and operational efficiency. However, there is room for improvement in EBIT and EBITDA margins, which suggest potential for enhanced operational performance.
Balance Sheet
65
Positive
The company's debt-to-equity ratio is 0.29, reflecting a conservative approach to leverage and strong equity financing. The equity ratio is 55.60%, indicating a robust financial position with a substantial portion of assets financed by equity. Return on Equity (ROE) is modest at 4.76% for 2024, suggesting average returns for shareholders. There is a need to enhance asset utilization and profitability to boost ROE.
Cash Flow
50
Neutral
Chia Tai Enterprises International faces challenges in cash flow management, as evidenced by no reported operating or free cash flow for 2024. The absence of positive cash flow suggests potential liquidity constraints. Historically, the company has struggled with consistent free cash flow generation, highlighting the need for improved cash flow efficiency and cost control.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue307.75M173.98M159.24M142.41M93.58M
Gross Profit48.93M33.77M39.19M34.76M24.90M
EBITDA17.51M11.29M5.17M20.86M23.73M
Net Income11.17M2.55M-4.26M26.70M16.25M
Balance Sheet
Total Assets422.21M377.37M350.58M365.22M330.70M
Cash, Cash Equivalents and Short-Term Investments32.38M37.61M30.86M31.09M32.26M
Total Debt69.17M78.17M49.10M42.61M20.50M
Total Liabilities161.70M125.36M94.83M81.69M80.09M
Stockholders Equity234.77M228.43M230.85M253.06M228.00M
Cash Flow
Free Cash Flow-2.56M-27.17M-10.38M-28.46M-9.23M
Operating Cash Flow11.29M-16.06M5.63M-10.91M4.03M
Investing Cash Flow-9.27M-7.14M-15.64M-9.84M-10.87M
Financing Cash Flow-7.07M30.23M10.38M19.36M249.00K

Chia Tai Enterprises International Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.00
Price Trends
50DMA
6.66
Positive
100DMA
4.55
Positive
200DMA
3.08
Positive
Market Momentum
MACD
0.83
Negative
RSI
66.08
Neutral
STOCH
77.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3839, the sentiment is Positive. The current price of 9 is above the 20-day moving average (MA) of 7.54, above the 50-day MA of 6.66, and above the 200-day MA of 3.08, indicating a bullish trend. The MACD of 0.83 indicates Negative momentum. The RSI at 66.08 is Neutral, neither overbought nor oversold. The STOCH value of 77.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3839.

Chia Tai Enterprises International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$2.38B11.6510.89%161.65%951.04%
70
Outperform
609.84M27.380.00%6.94%-1.99%-81.52%
66
Neutral
772.87M10.8910.74%8.32%-24.96%-26.43%
52
Neutral
506.30M71.430.60%6.67%-4.92%0.00%
49
Neutral
977.85M-4.02-51.07%-43.46%-96.48%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:3839
Chia Tai Enterprises International
9.00
8.20
1025.00%
HK:0455
Tianda Pharmaceuticals Ltd.
0.16
-0.08
-33.33%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.46
0.27
142.11%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.03
0.03
3.00%
HK:0239
Pak Fah Yeow International Limited
2.48
0.08
3.33%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.72
-0.13
-15.29%

Chia Tai Enterprises International Corporate Events

Chia Tai Enterprises Reports Strong Interim Results for 2025
Aug 11, 2025

Chia Tai Enterprises International Limited has announced its unaudited consolidated results for the six months ending June 30, 2025. The company reported a significant increase in revenue, reaching US$323.3 million compared to US$108 million in the same period last year. The gross profit also rose to US$41.8 million from US$18 million. The profit attributable to shareholders increased to US$17 million from US$2 million, reflecting a substantial improvement in financial performance. The total comprehensive income for the period was US$24.4 million, a notable turnaround from a loss in the previous year.

Chia Tai Enterprises Schedules Board Meeting for Interim Results and Dividend Decision
Jul 30, 2025

Chia Tai Enterprises International Limited has announced a board meeting scheduled for August 11, 2025, to approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 11, 2025